WO2016154020A1 - Procédés pour réduire la production et/ou l'excrétion de sébum - Google Patents

Procédés pour réduire la production et/ou l'excrétion de sébum Download PDF

Info

Publication number
WO2016154020A1
WO2016154020A1 PCT/US2016/023180 US2016023180W WO2016154020A1 WO 2016154020 A1 WO2016154020 A1 WO 2016154020A1 US 2016023180 W US2016023180 W US 2016023180W WO 2016154020 A1 WO2016154020 A1 WO 2016154020A1
Authority
WO
WIPO (PCT)
Prior art keywords
sebum
composition
skin
subject
peptide
Prior art date
Application number
PCT/US2016/023180
Other languages
English (en)
Inventor
Raja SIVAMANI
Vivian SHI
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2016154020A1 publication Critical patent/WO2016154020A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Definitions

  • Human skin is composed of three primary layers, the stratum corneum, the epidermis, and the dermis.
  • the outer layer is the stratum corneum. Its primary function is to serve as a barrier to the external environment.
  • Sebum an oily, waxy substance, is secreted to the surface of the stratum corneum by sebaceous glands. These glands are located over most of the surface of the body with the highest concentration on the scalp, forehead and face. Sebum acts to waterproof and lubricate the skin and hair of mammals.
  • sebum is primarily composed of triglycerides (about 41%), wax esters (about 26%), squalene (about 12%) free fatty acids (about 16%), cholesterol and cholesterol esters.
  • Seborrhea refers to the overproduction of sebum (i.e., sebaceous matter) in a sebaceous gland. Overproduction of sebum causes the sebaceous gland follicles to be partly or completely filled with sebum. Sebum can accumulate to an undesirable level in the sebaceous glands and form an ideal nutrient medium for microorganisms, such as, in particular, Propionibacterium acnes, a microorganism involved decisively in the development of acne. Thus, excessive sebum production is associated with an increased incidence of acne.
  • Areas of skin with increased sebum production are distinguished by an increased number of and/or activity of the sebaceous gland follicles and are preferentially to be found in the area of the face, and more preferentially on the forehead, nose, cheek, chin, hair-covered scalp; front and rear sweat channel; neck; chest and back. Accumulation of sebum on the surface of the skin can also cause the skin to appear shiny or oily and the hair to feel greasy.
  • a method for reducing sebum production and/or excretion in the skin of a subject in need thereof comprises administering to the subject an effective amount of a composition comprising a peptide that modulates neurotransmitter release, an equivalent thereof, a variant thereof, or a derivative thereof, and a pharmaceutically acceptable carrier to decrease sebum in the subject's skin.
  • the peptide that modulates neurotransmitter release can be at about 5% to about 20% by weight of the total composition.
  • the peptide that modulates neurotransmitter release is selected from the group consisting of acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, and any combination thereof.
  • compositions can be administered topically to the skin.
  • the composition is a formulation selected from the group consisting of a liquid, aqueous solution, suspension, cream, lotion, ointment, gel, foam and solid.
  • the pharmaceutically acceptable carrier of the composition can be a dermatologically acceptable carrier or a cosmetically acceptable carrier.
  • the subject has no symptom of a sebum overproduction condition.
  • the subject in need can have at least one symptom of a sebum overproduction condition, wherein the at least one symptom includes oily skin, combination oily to dry skin, dandruff, acne, greasy hair, or a combination thereof.
  • reducing sebum production and/or excretion includes an at least about 5% reduction in sebum after administration of the composition compared to before administration. In other embodiments, reducing sebum production and/or excretion includes an at least about 10% reduction in sebum after administration of the composition compared to before administration.
  • a method for treating a sebum overproduction condition in a subject in need thereof includes administering to the subject an effective amount of a composition comprising a peptide that modulates neurotransmitter release, an equivalent thereof, a variant thereof, or a derivative thereof, and a pharmaceutically acceptable carrier to decrease sebum in the subject's skin.
  • the peptide that modulates neurotransmitter release can be at about 5% to about 20%) by weight of the total composition.
  • the peptide that modulates neurotransmitter release can be selected from the group consisting of acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, and any combination thereof.
  • the composition is administered topically.
  • the composition is a formulation selected from the group consisting of a liquid, aqueous solution, suspension, cream, lotion, ointment, gel, foam and solid.
  • the pharmaceutically acceptable carrier of the composition can be a dermatologically acceptable carrier or a cosmetically acceptable carrier.
  • the subject suffers from a sebum overproduction condition selected from the group consisting of acne vulgaris, seborrhea, seborrheic dermatitis, sebopsoriasis, sebaceous hyperplasia, sebaceous cysts, hyperseborrhea, sebaceous carcinoma, acne conglobate, and a combination thereof.
  • the method further comprises alleviating at least one symptom of the sebum overproduction condition.
  • the at least one symptom can include reducing the appearance of oily skin, combination oily to dry skin, dandruff, acne, greasy hair, or a combination thereof.
  • the level of sebum in the skin is reduced by at least about 5% or at least about 10%> after administration of the composition.
  • the prophylactic method comprises administering to the subject an effective amount of a composition comprising a peptide that modulates neurotransmitter release, an equivalent thereof, a variant thereof, or a derivative thereof, and a pharmaceutically acceptable carrier to prevent excessive sebum production and/or excretion in the subject's skin.
  • the peptide that modulates neurotransmitter release can be at about 5% to about 20%) by weight of the total composition.
  • the peptide that modulates neurotransmitter release can be selected from the group consisting of acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, and any combination thereof.
  • the composition is a formulation selected from the group consisting of a liquid, aqueous solution, suspension, cream, lotion, ointment, gel, foam and solid.
  • the pharmaceutically acceptable carrier of the composition can be a dermatologically acceptable carrier or a cosmetically acceptable carrier.
  • preventing excessive sebum production and/or excretion can include an at least about 5% reduction in sebum production and/or excretion after administration of the composition compared to before administration.
  • preventing excessive sebum production and/or excretion includes an at least about 10% reduction in sebum production and/or excretion after administration of the composition compared to before administration. In some cases, the subject does not suffer from excessive sebum overproduction.
  • kits comprising a first composition comprising a peptide that modulates neurotransmitter release, an equivalent thereof, a variant thereof, or a derivative thereof, and a pharmaceutically acceptable carrier; and a second composition comprising a skin care composition or a hair care composition.
  • the peptide that modulates neurotransmitter release is at about 5% to about 20% by weight of the total composition.
  • the peptide that modulates neurotransmitter release is selected from the group consisting of acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, and any combination thereof.
  • the skin care composition can be selected from a skin cleanser, moisturizer, serum, lotion, anti-acne medication, anti-aging cream, sunscreen, and a combination thereof.
  • the hair care composition can be shampoo.
  • FIG. 1 illustrates sebocyte lipid production after acetyl hexapeptide-8 treatment.
  • FIG. 2 illustrates sebocyte proliferation after acetyl hexapeptide-8 treatment.
  • compositions provided herein may be administered to an individual to decrease the amount of sebum secreted by the individual's sebaceous glands.
  • the compositions containing a peptide that modulates neurotransmitter release such as acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, and any combination can be administered topically to the areas of the body with sebum production, such as the surface of the skin and hair.
  • the methods can be used to alleviate dermatological and cosmetic disorders as well as conditions that are associated with overproduction of sebum, including oily skin, oily hair, acne, seborrhea, and seborrheic dermatitis.
  • the methods and compositions can also be used prophylactically to prevent or reduce excessive sebum production.
  • treating refers to the treating or treatment of a disease or medical condition (such as a skin disease) in a patient, such as a mammal (particularly a human or an animal) which includes: ameliorating the disease or medical condition, i.e., eliminating or causing regression of the disease or medical condition in a patient; suppressing the disease or medical condition, i.e., slowing or arresting the development of the disease or medical condition in a patient; or alleviating one or more symptoms of the disease or medical condition in a patient.
  • the term encompasses the prophylactic treatment of a disease as to prevent or reduce the risk of acquiring or developing a specific disease, or to prevent or reduce the risk of disease recurrence.
  • administering refers to the process by which compounds, compositions, dosage forms and/or combinations disclosed herein are delivered to a subject for treatment or prophylactic purposes.
  • Compounds, compositions, dosage forms and/or combinations disclosed herein are administered in accordance with good medical practices taking into account the subject's clinical condition, the site and method of administration, dosage, subject age, sex, body weight, and other factors known to the physician.
  • administering or “administration” include providing, giving, dosing and/or prescribing compounds, compositions, dosage forms and/or combinations disclosed herein by a clinician or other clinical professional.
  • an effective amount or "a therapeutically effective amount” of a pharmaceutically active agent refers to an amount of the pharmaceutically active agent sufficient enough to have a desired effect on the area of application. Accordingly, these amounts are sufficient to modify the skin disorder, condition, or appearance to be treated but low enough to avoid serious side effects.
  • a therapeutically effective amount of the pharmaceutically active agent can cause relief of one or more symptoms when applied once or repeatedly over time. Effective amounts of the pharmaceutically active agent will vary with the particular condition or conditions being treated, the severity of the condition, the duration of the treatment, the specific components of the composition being used, and other factors that might have an influence on general effectiveness.
  • reducing sebum production refers to a reduction of the amount sebum of the skin, including a reduction of the sebum concentration in the skin, in particular in the sebaceous gland follicles, on the skin, on the hair-covered scalp, and/or on the hair, relative to the amount of sebum prior to administration.
  • This reduction of the sebum concentration of the skin can be determined, for example, by means of sebumetry, in particular by means of Sebutape ® -Chromameter (Cuderm), Sebufix (CK Electronic), Skin Analyzer SHP 88 (Concepts Computer), Skin Diagnostic SD 27(CK Electronic), or Sebumeter ® SM815 (CK Electronic).
  • the level of sebum at a specific location of the surface of the skin can be measured before administration of the composition and compared to the level of sebum at the same location after administration.
  • sebum overproduction or “excessive sebum production” refers to the production and/or secretion of sebum such that a subject's skin sebum level is higher than that of a normal, control subject, that of an average of normal, control subjects, that of the subject at an earlier time point.
  • Sebum overproduction includes, but is not limited to, increased sebocyte proliferation, increased production/synthesis of sebum, increased lipid production/synthesis by sebocytes, and increased sebum excretion or secretion.
  • Sebum overproduction can be determined by the presence of oily skin, oily and dry combination skin, greasy hair, pimples, skin pustules, papules, nodules and other skin issues due to acne.
  • Levels of sebum on the skin can be measured using standard methods by means of sebumetry, in particular by means of Sebutape ® -Chromameter (Cuderm), Sebufix (CK Electronic), Skin Analyzer SHP 88 (Concepts Computer), Skin Diagnostic SD 27(CK Electronic), or Sebumeter ® SM815 (CK Electronic). See, e.g., Pande and Misrl, Indian J Dermatol Venereol Leprol, 71(6):444-446 (2005).
  • a clinician e.g., dermatologist, can determine whether a subject is experiencing excessive sebum production or has a sebum overproduction condition.
  • sebum overproduction condition refers a condition or physical state of a subject that is caused by or associated with overproduction of sebum.
  • a sebum overproduction condition include acne vulgaris, seborrhea, seborrheic dermatitis, sebopsoriasis, sebaceous hyperplasia, sebaceous cysts, hyperseborrhea, sebaceous carcinoma, acne conglobate, or any combination thereof.
  • the condition can include any disease, disorder or condition that is caused by, associated with, or a side effect of producing, synthesizing, and/or secreting sebum at a level that is higher (e.g., at least 5% higher) than what is considered normal by a clinician, e.g., a dermatologist, or higher than a control value.
  • inhibiting refers to a measurable decrease or complete reduction to an achieve an expected, forecasted or intended result.
  • the term "preventing” refers to prophylactically averting or hindering an expected, forecasted or intended result.
  • pharmaceutically acceptable carrier includes any and all additives which are acceptable in the pharmaceutical sciences, and can include, for example, high molecular weight polymeric agents such as a cellulosic polymer, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, a vinylic polymer, polyvinylpyrolidone, polyvinyl alcohol, polyethylene glycol, petrolatum, talcum or other additives or binders.
  • a pharmaceutically acceptable carrier is pharmaceutically acceptable for use in humans.
  • skin acceptable carrier or “cosmetically acceptable carrier” can include, but is not limited to, water, salicylic acid, benzoyl peroxide, phenoxyethanol, butylene glycol, citric acid, propylene glycol, methylparaben, propylparaben, glycerin, chlorphenesin, sodium metabisulfite, and the like.
  • subject refers to any mammalian subject, particularly humans.
  • the subject can be a human of any age including those who are undergoing or have undergone puberty. In some cases, the human subject is an adult or at least 12 years old.
  • Peptides described herein include naturally occurring peptides and synthetic peptides that can serve as peptide mimetics of botulinum neurotoxins. These bioactive peptides can affect neurotransmitter release, for example, at neuromuscular junctions. In some cases, the peptide can inhibit acetylcholine release or binding. In some embodiments, the peptides include acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, and any combination thereof. [0032] The present invention is based, in part, on the surprising discovery that acetyl- hexapeptide-8 can decrease lipid production by sebocytes.
  • Acetyl hexapeptide-8 which is also referred to as AH8, acetyl hexapeptide-3 (AH3), and Argireline ® , is a synthetic cosmetics ingredient. It is a peptide fragment of SNAP-25, a substrate of botulinum toxin (Botox). Acetyl-hexapeptide-8 has the amino acid sequence of SEQ ID NO: l (Ac-Glu-Glu- Met-Gln-Arg-Arg- H 2 ).
  • Acetyl hexapeptide-8 having the chemical name acetyl glutamyl- glutamyl-methyonyl-glutamyl-arginyl-arginylamide (Argireline ® ), may be purchased from Lipotec S.A. in either a powder or solution form.
  • the powder form appears as a white to off- white powder comprising about 2.7 to 3.3% glutamic acid, about 0.6 to 1.0% methionine, and about 1.8 to 2.2%) arginine.
  • the solution form is a transparent solution containing about 0.05%) powder in water and about 0.5% preservative.
  • the composition described herein includes about 5% to about 20%, e.g., about 5-20%, about 5-15%, about 5-10%, about 10%-20%, about 10%- 15%, or about 15%-20% by weight of acetyl-hexapeptide-8.
  • the composition described herein includes about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%), about 19%), or about 20% by weight of acetyl-hexapeptide-8.
  • acetyl-hexapeptide-8 At concentrations such as at about 5% or more by weight of the total composition, acetyl-hexapeptide-8 has been shown to decrease sebocyte proliferation in the skin. At a range of from about 5% to about 20% by weight of the total weight to the total composition, acetyl-hexapeptide-8 can reduce lipid production by the sebaceous glands by at least about 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, compared to not applying acetyl- hexapeptide-8 to the subject's skin.
  • administration of acetyl-hexapeptide-8 can decrease sebum production, sebum excretion, or both in the skin by at least about 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%), 70%) or more, compared to not applying acetyl-hexapeptide-8 to the skin.
  • the decrease in sebum production, sebum excretion, or both is by at least about 10% or more, e.g., 10%, 11%, 12%, 13%, 14%, 15%, 16%. 17%. 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, compared to not applying acetyl-hexapeptide-8 to the skin.
  • lipid production is reduced by administration of acetyl-hexapeptide-8 such that the subject's skin is no longer oily to the touch or the subject's hair is no longer greasy after the treatment.
  • the oiliness of the subject's skin is reduced by at least about 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, after administering the acetyl- hexapeptide-8-containing composition to, e.g., the surface of the skin.
  • the greasiness of the subject's hair is reduced by at least 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%. 17%. 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, after administering the acetyl-hexapeptide-8-containing composition to, e.g., the hair and/or scalp.
  • the amount of sebum or lipid production and/or excretion by the sebaceous glands directly corresponds to the level of sebum on the surface of a subject's skin.
  • acetyl-hexapeptide-8- containing composition can diminish the appearance of oily skin, combination oily to dry skin, dandruff, acne, greasy hair, or a combination thereof.
  • the peptide that modulates neurotransmitter release can be a peptide mimetic of the botulinum neurotoxins (BoNT).
  • the peptide can be RT001 or RTT150 from Revance Therapeutics (Newark, California) or other peptide mimetics of BoNT -A or the other BoNT serotypes.
  • the peptide can be synthetic pentapeptide-3 such as Vialox ® (Pentapharma; Basel, Switzerland).
  • the pentapeptide-3 or equivalent thereof can antagonize the acetylcholine postsynaptic membrane receptor.
  • the peptide can be pentapeptide with an encephalin-like structure such as Leuphasyl ® (Lipotec S.A.; Barcelona, Spain).
  • the peptide can be tripeptide-3 (beta-Ala-Pro-Dab-NH-benzyl x 2 AcOH) that functions similarly to walglerin-1 such as Syn ® -Ake (Pentapharma).
  • the tripeptide-3 or equivalent thereof can antagonize the muscular nicotinic acetylcholine receptor at the postsynaptic membrane. Detailed descriptions of these peptides are found, e.g., in Reddy et al., Exp Dermatol, 2012, 21(8): 569-75. Additional useful peptides can include bioactive peptides that can be used to reduce the depth of wrinkles and/or number of wrinkles of the skin.
  • the composition described herein includes about 5% to about 20%, e.g., about 5-20%, about 5-15%, about 5-10%, about 10%-20%, about 10%- 15%, or about 15%-20% by weight of any of the peptides described herein. In other embodiments, the composition described herein includes about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%), about 18%, about 19%, or about 20% by weight of any of the peptides described herein.
  • one or more of the peptides described herein has been shown to decrease sebocyte proliferation.
  • one or more of the peptides can reduce lipid production by the sebaceous glands by at least about 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, compared to not applying the peptide(s) to the subject's skin.
  • administration of one or more of the peptides can decrease sebum production and/or secretion by at least about 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, compared to not applying the peptide(s) to the skin.
  • the decrease in sebum production, sebum excretion or both is by at least about 10% or more, e.g., 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%), 60%), 65%), 70%) or more, compared to not applying the peptide(s) to the skin.
  • one or more, e.g., 1, 2, 3, 4 or more peptides are formulated together in the composition.
  • lipid production is reduced by administration of one or more of the peptides such that the subject's skin is no longer oily to the touch or the subject's hair is no longer greasy after the treatment.
  • the oiliness of the subject's skin is reduced by at least about 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%), 65%), 70%) or more, after administering the peptide-containing composition to, e.g., the surface of the skin.
  • the oiliness of the subject's skin is reduced by at least about 10% or more, e.g., about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, after administering the peptide- containing composition to, e.g., the surface of the skin.
  • the greasiness of the subject's hair is reduced by at least 5% or more, e.g., about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or more, after administering the peptide-containing composition to, e.g., the hair and/or scalp.
  • the greasiness of the subject's hair is reduced by at least 10% or more, e.g., about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%), 65%), 70%) or more, after administering the peptide-containing composition to, e.g., the hair and/or scalp.
  • the amount of sebum production or excretion by the sebaceous glands directly corresponds to the level of sebum on the surface of a subject's skin.
  • the peptide-containing composition can be administered to a subject as a prophylactic treatment for sebum overproduction.
  • the composition described herein can prevent an increase in sebum production in a subject.
  • the sebum level of the subject's skin can decrease, remain substantially unchanged, remain unchanged, or increase by no more than about 3%, e.g., about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%), 2.9%), 3%), compared to the sebum level prior to treatment.
  • the level of sebum in skin decreases by at least about 5%, e.g., 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, more after administration of the composition. In other embodiments, the level of sebum in skin decreases by at least about 10%, e.g., 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, or more after administration of the composition.
  • the peptide composition can be administered in a quantity sufficient to reduce, inhibit or prevent the production or secretion of sebum by sebaceous glands.
  • acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, or any combination thereof can reduce the level of sebum on the skin of a subject following administration.
  • administration of acetyl hexapeptide-8, RT001, Vialox ® , Leuphasyl ® , Syn ® -Ake, or any combination thereof can prevent an increase in the level of sebum on the skin of a subject who oily skin, combination oily to dry skin, dandruff, acne, greasy hair, or a combination thereof.
  • the peptide composition can be administered to a subject who does not have oily skin, combination oily to dry skin, dandruff, acne, greasy hair, or a combination thereof.
  • the subject may have normal skin. For instance, upon applying the composition to the skin to this subject, the level of sebum will remain substantially unchanged.
  • the peptide composition can be used to decrease sebum production and/or sebum excretion in a subject that exhibits one or more symptoms of a sebum over production condition.
  • the dermatological composition can be used to treat a sebum overproduction condition including any condition that is characterized by an increased sebum level as determined by, for example, a sebumeter.
  • the amount required can vary depending upon the particular disorder or condition being treated, the severity of the patient's disorder or condition, the route of administration, the presence of other underlying disorders or conditions, and the like.
  • the peptide containing composition can be administered systemically or locally at a dosage range sufficient to alleviate at least one symptom of any of the diseases or conditions described herein.
  • the peptide-containing composition can be applied at intervals to achieve effective results.
  • the peptide-containing composition can be topically applied once a day.
  • application can be at least once a day, twice a day, or more frequently.
  • Repetitive daily administration e.g., administration 2 times, 3 times, 4 times, 5 times or more per day, may be desirable and will vary according to the conditions set forth herein.
  • application that occurs less frequently e.g., administration once, twice, three, or four times a week or month, may be desirable and will vary according to the conditions set forth herein.
  • Treatment periods will depend on the severity of the condition and also whether the peptide compound is being applied as a preventative measure for the development of oily skin or after oily skin has emerged or the more serious acne or seborrhea manifestation exists.
  • the treatment period can be 1 week or more, e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.
  • the frequency and duration of application e.g., topical administration, may vary from person to person.
  • a significant reduction in the oily appearance of skin or hair can occur after 1 or more weeks, e.g., after 1, 2, 3, 4, 5, 6, 7, 8 or more weeks, of administration.
  • the method includes administering the composition containing acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, or any combination thereof for a length of time such that the appearance of sebum production is reduced, decreased or minimized compared to before the initial administration.
  • the compound of the present invention may be administered by a variety of routes. It has been shown to be effective if administered topically.
  • the compounds may also be administered parenterally (i.e., subcutaneously, intravenously, intramuscularly, intraperitoneally, or intrathecally), rectally, or orally.
  • the peptide such as acetyl hexapeptide-8, RT001, Vial ox ® , Leuphasyl ® , Syn ® -Ake, or any combination thereof is administered topically. Topical administration is especially appropriate for acne, seborrhea, and for dermatological and cosmetic indications.
  • the compound can be applied to those areas of the skin afflicted with excess sebum production, such as the face, neck, hair and scalp.
  • the peptide-containing composition can be administered to one or more sites on the skin that may exhibit increased sebum levels.
  • the topical formulation dependent on its nature, can be simply applied with a finger or through incorporation in a suitable substrate such as a suitable fabric.
  • the composition can be used for localized topical application.
  • the composition can be applied to a specific localized area of the skin to target a specific skin condition.
  • the composition can be administered to the skin surface of any part of the body including, but not limited to, the face, neck, scalp, arms, chest, buttocks, abdomen, and legs.
  • the dose will vary, but as a general guideline, the compound can be present in a dermatologically or cosmetically acceptable carrier in an amount of from about 5% to about 20% by weight of the total composition, e.g., about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%), about 17%, about 18%>, about 19%, about 20% by weight.
  • a dermatologically or cosmetically acceptable carrier in an amount of from about 5% to about 20% by weight of the total composition, e.g., about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%), about 17%, about 18%>, about 19%, about 20% by weight.
  • the dermatological or cosmetic preparation can be applied to the affected area when needed, such as upon the appearance of oily skin, greasy hair, or acne associated blackheads, whiteheads, pimples, microcomedones, comedones, papules, pustules, nodules, large papules, or scarring.
  • the term "dermatologically acceptable carrier” refers to a carrier which may be applied to the skin, hair or scalp, and which will allow the drug to diffuse to the site of action (e.g., the sebaceous glands, the sebocytes and/or the acinar cells).
  • the term "cosmetically acceptable carrier” refers to a carrier that provides a composition with particular tactile properties which feel pleasant on the skin or hair (e.g., compositions that are not too watery or greasy, compositions that have a silky texture, compositions that are non-tacky or sticky, etc.).
  • a cosmetically acceptable carrier can be suitable for the application or spreading of a composition onto the surface of skin or hair.
  • compositions can include a cosmetically acceptable carrier to act as a diluent, dispersant or carrier for the active ingredients, so as to facilitate its distribution and uptake when the composition is applied to the skin.
  • Vehicles can include water, liquid or solid emollients, solvents, humectants, thickeners, powders, and perfumes, some of which have been described above.
  • a suitable carrier may include, for example, glycerin, butylene glycol, propylene glycol, water, various oils (e.g., jojoba, sweet almond, soybean, sunflower, apricot, etc.), and the like.
  • compositions can be applied on skin directly without any other preparation.
  • the compositions can be applied to the skin after the skin is thoroughly cleaned and dried prior to application of the peptide containing composition.
  • the methods of the present invention can also include applying an additional sebum control agent, such as but not limited to, capryloyl glycine, cinnamomum zeylanicum bark extract and/or sarcosine.
  • an additional sebum control agent such as but not limited to, capryloyl glycine, cinnamomum zeylanicum bark extract and/or sarcosine.
  • Conditions associated with sebum overproduction are methods for preventing, arresting, reversing, decreasing, reducing, diminishing, or inhibiting sebum production (e.g., abnormal sebum production or excessive sebum production) in a subject in need thereof.
  • the method can be used to reduce the amount of sebum on oily skin or on skin having a shiny appearance.
  • the method can be used to reduce the amount of sebum on oily (greasy) hair or on hair having a shiny (greasy) appearance.
  • the subject has a baseline sebum excretion rate (SER) of 40 ⁇ g/cm 2 /min or higher, as determined using a Sebumeter ® (Courage and Khazaka, Cologne, Germany) or an equivalent device or method.
  • the baseline facial SER can be obtained by measuring the SER for at least two facial zones, such as the right and left forehead, and/or right and left cheek, and averaged over the measured areas.
  • the baseline facial SER can be determined for one facial zone, such as the left forehead, right forehead, left cheek, right cheek, nose, chin, scalp and the like.
  • the subject's facial SER is at least 40 ⁇ g/cm 2 /min, 50 ⁇ g/cm 2 /min, 60 ⁇ g/cm 2 /min, 70 ⁇ g/cm 2 /min, 80 ⁇ g/cm 2 /min, 90 ⁇ g/cm 2 /min, 100 ⁇ g/cm 2 /min, 110 ⁇ g/cm 2 /min, 120 ⁇ g/cm 2 /min, 130 ⁇ g/cm 2 /min, 140 ⁇ g/cm 2 /min, 150 ⁇ g/cm 2 /min, 160 ⁇ g/cm 2 /min, 170 ⁇ g/cm 2 /min, 180 ⁇ g/cm 2 /min, or higher.
  • the subject's baseline SER is 40 ⁇ g/cm 2 /min or less, e.g., 40 ⁇ g/cm 2 /min, 30 ⁇ g/cm 2 /min, 20 ⁇ g/cm 2 /min, 10 ⁇ g/cm 2 /min J or less.
  • the sebum excretion rate can be measured at the skin surface of any part of the body including, but not limited to, the face, neck, scalp, arms, chest, buttocks, abdomen, and legs.
  • a subject with a baseline SER of 40 ⁇ g/cm 2 /min or higher e.g., 40 ⁇ g/cm 2 /min, 50 ⁇ g/cm 2 /min, 60 ⁇ g/cm 2 /min, 70 ⁇ g/cm 2 /min, 80 ⁇ g/cm 2 /min, 90 ⁇ g/cm 2 /min, 100 ⁇ g/cm 2 /min, 110 ⁇ g/cm 2 /min, 120 ⁇ / ⁇ 2 /min, 130 ⁇ g/cm 2 /min, 140 ⁇ / ⁇ 2 /min, 150 ⁇ / ⁇ 2 /min, 160 ⁇ g/cm 2 /min, 170 ⁇ / ⁇ 2 /min, 180 ⁇ g/cm 2 /min, or higher is selected to be administered the composition comprising one or more peptides that modulate neurotransmitter release.
  • the subject may have normal skin, normal to oily skin, oily skin, or a combination thereof.
  • the subject may also have a disorder or condition
  • disorders or conditions associated with overproduction of sebum by sebaceous glands can be treated with the methods and compositions provided herein.
  • disorders or conditions include acne vulgaris, inflammatory acne, comedonal acne, papulopustular acne, nodular acne, acne conglobate, exogenous acne, seborrhea, seborrheic dermatitis, sebopsoriasis, sebaceous hyperplasia, sebaceous cysts, hyperseborrhea, sebaceous carcinoma, acne conglobate, or any combination thereof.
  • disorders that can be treated using the composition described herein can be directly or indirectly due to sebum production, sebum secretion, sebocyte proliferation, sebocyte growth, sebocyte maturation, sebum synthesis, sebum turnover, abnormal sebum composition, and the like.
  • the peptide-containing composition pf the present disclosure can be used to prevent or treat one or more of the conditions described above.
  • the subject has acne.
  • the subject has mild acne vulgaris or moderate to severe acne vulgaris.
  • the subject has grade 1 (almost clear acne), grade 2 (mild acne), grade 3 (moderate acne), or grade 4 (severe acne) acne on the Investigator's Global Assessment (IGA).
  • the peptide compounds can be administered directly without any carrier. However, to ease administration, they will typically be formulated into pharmaceutical carriers.
  • the peptide compound can be incorporated into formulations suitable for topical administration. Any of the topical formulations known in the art may be used. Examples of such topical formulations include lotions, sprays, creams, ointments, salves, gels, etc. Actual methods for preparing topical formulations are known or apparent to those skilled in the art, and are described in detail in Remington's Pharmaceutical Sciences, 1990 (supra); and Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed., Williams & Wilkins (1995).
  • the topical formulations may be in the form of a homogeneous phase formulation or in the form of an emulsion or microemulsion including, but not limited to, oil-in-water, water-in-oil and multiple including triple, phase emulsions.
  • emulsions can cover a broad range of consistencies including thin lotions (which can also be suitable for spray or aerosol delivery), creamy lotions, light creams and heavy creams.
  • suitable topical carriers include anhydrous liquid solvents such as oil and alcohol; aqueous-based single phase liquid solvent ⁇ e.g., hydro-alcoholic solvent system); anhydrous solid and semisolid (such as gel and stick); and aqueous based gel and mousse system.
  • the composition may additionally include one or more anesthetics, anti- allergenics, anti-irritants, antifungal agents, anti-microbial agents, anti-inflammatory agents, antiseptics, chelating agents, colorants, whitening or depigmenting agents, exfoliating agents, emollients, emulsifiers, film formers, fragrances, humectants, insect repellents, lubricants, moisturizers, pharmaceutical agents, photostabilizing agents, vitamins, preservatives, perfumes, plant extracts, essential oils, mineral salts, cell extracts, marine extracts, skin protectants, skin penetration enhancers, skin conditioners, sunscreens, stabilizers, surfactants, thickeners, viscosity modifiers, pigments or dyes, anti-wrinkle agents, anti-aging agents, anti- free radical agents, cleansers, or any combinations thereof.
  • anesthetics include one or more anesthetics, anti- allergenics, anti-irritants, antifungal agents, anti-m
  • a pharmaceutically or cosmetically acceptable vehicle may also be included in the composition.
  • cosmetically acceptable vehicles include water, C 1 -C 4 alcohols, fatty alcohols, fatty ethers, fatty esters, glycerin, glycols, vegetable oils, mineral oils, lecithin, hydrogenated lecithin, liposomes, laminar lipid materials, phospholipids, polyglycols, polyols, propyl alcohol, silicone oils, vegetable oil, or any combinations thereof.
  • Peptide compounds of the present invention can be added to dermatological or cosmetic compositions.
  • Non-limiting examples of cosmetic compositions include sunscreen products, sunless skin tanning products, hair products, e.g., shampoos and conditioners, moisturizing creams, serums, skin benefit creams and lotions, softeners, day lotions, gels, ointments, foundations, night creams, eyeshadows, eyeliners, cheek colors, cleansers, toners, masks, or other known cosmetic products or applications.
  • the compositions of the present invention include additional cosmetic ingredients.
  • CTFA International Cosmetic Ingredient Dictionary and Handbook (2004 and 2008 versions) describes a wide variety of non-limiting cosmetic ingredients that can be used.
  • fragrances artificial and natural
  • dyes and color ingredients e.g., Blue 1, Blue 1 Lake, Red 40, titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10, and D&C yellow no.
  • adsorbents emulsifiers
  • stabilizers emulsifiers
  • lubricants solvents
  • moisturizers including, e.g., emollients, humectants, film formers, occlusive agents, and agents that affect the natural moisturization mechanisms of the skin
  • water-repellants UV absorbers (physical and chemical absorbers such as paraminobenzoic acid (“PABA”) and corresponding PABA derivatives, titanium dioxide, zinc oxide, avobenzone, octocrylene, oxybenzone, homosalate, octinocate, octisalate, etc.), essential oils, vitamins (e.g., A, B, C, D, E, and K), trace metals (e.g., zinc, calcium and selenium), anti-irritants (e.g., steroids and non-steroidal anti -inflammatories), botanical extracts (e.g., aloe vera, chamomile, cucumber extract
  • the peptide compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions, or emulsions.
  • Solid unit dosage forms can be capsules of the ordinary gelatin type containing, for example, surfactants, lubricants and inert fillers such as lactose, sucrose, and cornstarch or they can be sustained release preparations.
  • the compounds can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders, such as acacia, cornstarch, or gelatin, disintegrating agents such as potato starch or alginic acid, and a lubricant such as stearic acid or magnesium stearate.
  • binders such as acacia, cornstarch, or gelatin
  • disintegrating agents such as potato starch or alginic acid
  • a lubricant such as stearic acid or magnesium stearate.
  • Liquid preparations are prepared by dissolving the active ingredient in an aqueous or non-aqueous pharmaceutically acceptable solvent, which may also contain suspending agents, sweetening agents, flavoring agents, and preservative agents as are known in the art.
  • a physiologically acceptable pharmaceutical carrier for parenteral administration the peptide compounds may be dissolved in a physiologically acceptable pharmaceutical carrier and administered as either a solution or a suspension.
  • Suitable pharmaceutical carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative, or synthetic origin.
  • the pharmaceutical carrier may also contain preservatives, buffers, etc., as are known in the art. E. Assaying sebum production
  • the level of sebum production by an individual can be measured using commercially available sebutape or by means of a sebumeter.
  • Sebutape is a microporous patch available from CeDerm Corporation. Sebutape detects sebum production without the use of any solvents, powders, or chemicals.
  • the microporous patch acts as a passive collector of sebum. Gradual displacement of air in the pores of the patch changes the patches appearance. The sebum filled pores in the patch do not scatter light and thus appear transparent. The size of the transparent area is a measure of the amount of sebum collected.
  • Patches can be placed on a dark background storage card for evaluation by eye or by computer imaging (Eisner (1995) in “BIOENGINEERING OF THE SKIN: METHODS AND INSTRUMENTATION,” Berardesca et al, eds., 81-89, CRC Press, Boca Raton, Fla.).
  • Sebum production can also be measured by means of a device referred to in the art as a sebumeter, for example, a model SM810 PC sebumeter, available from Courage & Khazaka (Koln, Germany).
  • a sebumeter measures the content of sebum in the stratum comeum of skin, the values of which are expressed in micrograms/cm 2 or micrograms/cm 2 /minute.
  • the sebumeter can be fitted with a manual data collector which has a band designed to absorb skin sebum. The band is 0.1 mm thick and has a 64 mm 2 contact surface. The higher the amount of lipids present in the band, the higher the film transparency.
  • numeric values shown on the display are directly proportional to the band transparency and thereby to the amount of lipids present in the band itself (Eisner (1995), supra, and Clarys and Barel (1995) Quantitative Evaluation of Skin Surface Lipids, CLINICS IN DERMATOLOGY 13 : 307-321).
  • any method known to one of ordinary skill in the art can be used to measure or determine whether the compositions provided herein can modulate sebum production or secretion.
  • Luderschmidt et al. ⁇ Arch Derm Res, 258: 185-191 (1977) describes an animal model for testing dermatological compounds on the lipid production of sebaceous glands. The method includes treating the ear of Syrian hamster with a test compound and measuring the lipid content of the treated tissue using HPLC analysis. Detailed descriptions of this assay method are found in, e.g. , U. S. Patent Application Publication No. 2013/0178446.
  • administration of the peptide containing composition reduces a subject's SER by at least 5%, e.g. , 5%, 6%, 7%, 8%, 9%, 10%, 1 1%, 12%, 13%, 14%, 15%, 16%), 17%), 18%), 19%), 20%) or more from baseline after at least two weeks, e.g. , 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 1 1 months, 1 year or more of treatment.
  • an at least 20% reduction of SER is achieved over at least two weeks, e.g., 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 1 1 months, 1 year or more of treatment.
  • Kits are also contemplated as being used in certain aspects of the present invention.
  • a composition of the present invention can be included in a kit.
  • the composition can include a peptide disclosed herein formulated as a liquid, solution, suspension, cream, lotion, moisturizer, ointment, gel, foam or solid.
  • the kit includes the peptide and a cosmetic or dermatological agent such as a lotion, cream, ointment, serum, sunscreen, anti-acne medication, shampoo, conditioner, cleanser, toner, mask, skin softener, foundation, night cream, sunless tanning product, hair product, skin benefit product, skin protectant, or other cosmetic or dermatological agent.
  • the peptide is present in an amount that is about 5% to about 20% by weight of the total weight of the composition or formulation of the kit.
  • a kit can include a container.
  • Containers can include a bottle, a metal tube, a laminate tube, a plastic tube, a dispenser, a pressurized container, a barrier container, a package, a compartment, a compact container, or other types of containers such as injection or blow-molded plastic containers into which the dispersions or compositions or desired bottles, dispensers, or packages are retained.
  • the containers can dispense a pre-determined amount of a composition.
  • the container can be squeezed (e.g., metal, laminate, or plastic tube) to dispense a desired amount of the composition.
  • the composition can be dispensed as a spray, an aerosol, a liquid, a fluid, or a semi-solid.
  • the containers can have spray, pump, or squeeze mechanisms.
  • a kit can also include instructions for using the kit and/or compositions. Instructions can include an explanation of how to apply, use, and maintain the compositions.
  • Example 1 Reduction of lipid production by sebocytes after treatment with acetyl hexapeptide-8 (Argireline ® ).
  • Argireline ® acetyl hexapeptide-8; AH8
  • AH8 acetyl hexapeptide-8
  • Intradermal botulinum injection has shown promising results for the treatment of acne vulgaris, a condition with excessive sebum production.
  • Argireline ® has a direct effect on sebocytes.
  • Argireline ® can directly alter sebocytes lipid synthesis and cell proliferation, and attempt to examine the mechanism at which it regulates sterol biosynthesis.
  • SEB-1 human sebocytes were treated with increasing concentrations of Argireline peptide solution (0.00005% or 1 : 1000, 0.0005% or 1 : 100, 0.005% or 1 : 10, and 0.025% or 1 :2) and incubated for 48 hours. PBS was used as negative control treatments. Nile red was used for lipid content measurement and normalized to cell count using DAPI.
  • Sebocytes treated with 0.0005%> Argireline ® solution were lysed for protein collection and western blot analysis for expression of sterol regulatory element binding protein-1 (SREBP-1), a key regulator of sterol biosynthesis. GAPDH expression was used as an internal reference.
  • SREBP-1 sterol regulatory element binding protein-1
  • Sebocyte proliferation was unchanged at the Argireline ® concentrations of 0.00005%), 0.0005%) and 0.005% (FIG. 2).
  • Argireline ® concentration of 0.025% (1 :2) sebocyte proliferation was markedly decreased compared to untreated control sebocytes (FIG. 2). Sebocytes exhibited no significant difference in the expression of SREBP-1 (a lipid synthesis transcription factor) after 0.0005% Argireline ® treatment.
  • Argireline ® inhibits sebaceous production and/or accumulation of lipid in vitro. Sebocyte proliferation was unchanged at the lower concentrations of Argireline ® tested. SREBP-1 expression was also unchanged following 0.0005%> Argireline ® treatment.
  • the data in this example clearly demonstrate that Argireline ® can be used as an agent to reduce or inhibit sebocyte lipid production and/or accumulation. As such, Argireline ® can be used to treat or prevent conditions associated with sebum overproduction, such as acne and seborrhea.
  • Example 2 Reduction of sebum excretion rate in patients treated with Argireline ® .
  • the study described herein examined the effects of Argireline on 12 healthy adult volunteers. Subjects had a range of baseline sebum excretion rates, ranging from low to high rates. None of the subjects were taking a medication that affects sebum levels, and none exhibited a facial skin condition such as acne, dermatitis, psoriasis, rosacea, and the like.
  • Each subject was given blindly labeled tubes containing either an Argireline ® treatment (10% (by weight) solution of Argireline ® in facial moisturizing lotion (Cetaphil ® )) or a vehicle treatment (facial moisturizing lotion (Cetaphil ® ) alone). They were instructed to apply either treatment to the right or left side once a day. In other words, for each subject one side of the face was treated with Argireline ® and the other side was treated with vehicle. The subjects were assessed 2 weeks after the initial application (week 2 follow-up). The facial sebum excretion rate (SER) was evaluated using a Sebumeter ® (Courage-Khazaka, Koln, Germany).
  • SER facial sebum excretion rate
  • the results of the study demonstrate that application of Argireline ® can decrease sebum production, sebum excretion (sebum secretion) and/or the amount of sebum on the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés, des compositions et des trousses permettant de réduire ou de prévenir la production et/ou l'excrétion excessive de sébum par un sujet. Le procédé comprend l'administration d'une composition comprenant un peptide qui peut moduler la libération de neurotransmetteurs tels que l'hexapeptide-8 d'acétyle RT001, le Vialox®, le Leuphasyl®, le Syn®-Ake, et toute combinaison de ceux-ci. Le procédé peut inclure l'administration topique de la composition. L'invention concerne également des procédés, des compositions et des trousses pour traiter ou prévenir un état associé à la surproduction ou à l'excrétion excessive de sébum, y compris la séborrhée et l'acné.
PCT/US2016/023180 2015-03-20 2016-03-18 Procédés pour réduire la production et/ou l'excrétion de sébum WO2016154020A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562136027P 2015-03-20 2015-03-20
US62/136,027 2015-03-20

Publications (1)

Publication Number Publication Date
WO2016154020A1 true WO2016154020A1 (fr) 2016-09-29

Family

ID=56978534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/023180 WO2016154020A1 (fr) 2015-03-20 2016-03-18 Procédés pour réduire la production et/ou l'excrétion de sébum

Country Status (1)

Country Link
WO (1) WO2016154020A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017102591A1 (fr) * 2015-12-16 2017-06-22 Dsm Ip Assets B.V. Nouvelle utilisation
CN107698663A (zh) * 2017-11-20 2018-02-16 陕西慧康生物科技有限责任公司 一种维洛丝肽的液相合成方法
CN114376928A (zh) * 2021-12-30 2022-04-22 广州一一生物技术有限公司 一种控油、祛痘护肤组合物及其制备方法
WO2023186193A1 (fr) * 2022-03-31 2023-10-05 Contipro A.S. Hexapeptide, composition comprenant celui-ci et son utilisation topique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074466A1 (en) * 2001-07-27 2005-04-07 Suskind Dana L. Botulinum toxin in the treatment or prevention of acne
US8153139B1 (en) * 2002-08-19 2012-04-10 Ira Sanders Treatment of rosacea with clostridia neurotoxins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074466A1 (en) * 2001-07-27 2005-04-07 Suskind Dana L. Botulinum toxin in the treatment or prevention of acne
US8153139B1 (en) * 2002-08-19 2012-04-10 Ira Sanders Treatment of rosacea with clostridia neurotoxins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ATAMOROS, FP: "Topical botulinum toxin type A for the treatment of moderate to severe lateral canthal lines: Preliminary safety and efficacy results of a blinded, randomized, placebo control trials.", August 2009 (2009-08-01), pages 1, XP055315802, Retrieved from the Internet <URL:www.revance.com/pdfs/safety-study-topical-type-A-mexico-1.pdf> *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017102591A1 (fr) * 2015-12-16 2017-06-22 Dsm Ip Assets B.V. Nouvelle utilisation
JP2018537462A (ja) * 2015-12-16 2018-12-20 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 新規な使用
US10561702B2 (en) 2015-12-16 2020-02-18 Dsm Ip Assets B.V. Method for the treatment of skin disorders using dipeptide diaminobutyroyl benzylamide diacetate
JP7115310B2 (ja) 2015-12-16 2022-08-09 ディーエスエム アイピー アセッツ ビー．ブイ． 新規な使用
CN107698663A (zh) * 2017-11-20 2018-02-16 陕西慧康生物科技有限责任公司 一种维洛丝肽的液相合成方法
CN114376928A (zh) * 2021-12-30 2022-04-22 广州一一生物技术有限公司 一种控油、祛痘护肤组合物及其制备方法
CN114376928B (zh) * 2021-12-30 2023-08-29 广州一一生物技术有限公司 一种控油、祛痘护肤组合物及其制备方法
WO2023186193A1 (fr) * 2022-03-31 2023-10-05 Contipro A.S. Hexapeptide, composition comprenant celui-ci et son utilisation topique

Similar Documents

Publication Publication Date Title
CN105189531B (zh) 用于皮肤复新的肽及其使用方法
JP4256389B2 (ja) テトラペプチドとトリペプチドの混合物を含む組成物
AU2020273346B2 (en) Methods and compositions for topical delivery for skin care
EP2624806B1 (fr) Compositions cosmetiques de soin de la peau
US20100247693A1 (en) Cosmetic formulation to treat rosacea telangiectasia
US20120094919A1 (en) Use of tripeptides
AU2005204685A1 (en) Cosmetic composition and method for retarding hair growth
US20210338634A1 (en) Putrescine slow-release topical formulations
WO2005077111A2 (fr) Methode et preparation visant a reduire l&#39;hyperpigmentation cutanee
US20160175223A1 (en) Anti-aging compositions comprising bile acid-fatty acid conjugates
WO2016154020A1 (fr) Procédés pour réduire la production et/ou l&#39;excrétion de sébum
US20080057138A1 (en) Restorative skin cream
US11918666B2 (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
US20120064020A1 (en) Novel composition
US9572767B2 (en) Luminate hand cream
US20050281853A1 (en) Skin compatible cosmetic compositions and delivery methods therefor
US20230000759A1 (en) Ppar agonist complex and methods of use
CN113616539A (zh) 化妆品组合物
WO2022167984A1 (fr) Composition et procédé d&#39;exfoliation non thérapeutique de l&#39;épiderme
TR2023018194A2 (tr) Sali̇si̇li̇k asi̇t, hi̇ndi̇stan cevi̇zi̇ yaği, vi̇tami̇n c ve vi̇tami̇n e?yi̇ kombi̇ne halde i̇çeren nanoemülsi̇yon bazli nanokrem formülasyonlari

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16769424

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16769424

Country of ref document: EP

Kind code of ref document: A1